AQR Capital Management LLC Takes Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

AQR Capital Management LLC bought a new stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO) in the second quarter, HoldingsChannel.com reports. The institutional investor bought 27,287 shares of the company’s stock, valued at approximately $64,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Nisa Investment Advisors LLC lifted its stake in shares of Allogene Therapeutics by 429.6% in the 2nd quarter. Nisa Investment Advisors LLC now owns 10,767 shares of the company’s stock valued at $25,000 after acquiring an additional 8,734 shares during the last quarter. Federated Hermes Inc. bought a new stake in shares of Allogene Therapeutics in the 2nd quarter valued at about $29,000. Phoenix Wealth Advisors bought a new stake in shares of Allogene Therapeutics in the 2nd quarter valued at about $30,000. Rothschild Investment LLC bought a new stake in shares of Allogene Therapeutics in the 2nd quarter valued at about $52,000. Finally, Headlands Technologies LLC bought a new stake in shares of Allogene Therapeutics in the 1st quarter valued at about $78,000. Institutional investors own 83.63% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on ALLO. Oppenheimer began coverage on Allogene Therapeutics in a report on Thursday, August 8th. They set an “outperform” rating and a $11.00 price target on the stock. Truist Financial restated a “buy” rating and set a $14.00 price target (down previously from $17.00) on shares of Allogene Therapeutics in a report on Friday, August 9th. Canaccord Genuity Group reduced their price target on Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Citigroup boosted their price target on Allogene Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Allogene Therapeutics in a report on Thursday, August 15th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Allogene Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $9.96.

Allogene Therapeutics Stock Up 5.6 %

Shares of ALLO opened at $2.84 on Friday. The business’s 50 day moving average price is $2.65 and its 200-day moving average price is $2.77. Allogene Therapeutics, Inc. has a 52 week low of $2.01 and a 52 week high of $5.78. The stock has a market cap of $593.56 million, a P/E ratio of -1.59 and a beta of 0.83.

Allogene Therapeutics (NASDAQ:ALLO) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. Allogene Therapeutics had a negative return on equity of 50.24% and a negative net margin of 223,139.98%. On average, equities analysts anticipate that Allogene Therapeutics, Inc. will post -1.38 EPS for the current year.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).